PortugalTuberculosis profile
Population  2015 10 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.21 (0.21–0.22) 2.1 (2–2.1)
Mortality (HIV+TB only) 0.046 (<0.01–0.23) 0.45 (0–2.2)
Incidence  (includes HIV+TB) 2.4 (2.1–2.8) 23 (20–27)
Incidence (HIV+TB only) 0.35 (0.29–0.41) 3.4 (2.8–3.9)
Incidence (MDR/RR-TB)** 0.033 (0.019–0.047) 0.32 (0.18–0.45)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.074 (0.035–0.11) 0.73 (0.47–0.99) 0.81 (0.51–1.1)
Males 0.11 (0.079–0.15) 1.5 (1.2–1.8) 1.6 (1.2–1.9)
Total 0.19 (0.14–0.23) 2.2 (2–2.4) 2.4 (2.1–2.8)
TB case notifications, 2015  
Total cases notified 2 124
Total new and relapse 2 087
          - % tested with rapid diagnostics at time of diagnosis 14%
          - % with known HIV status 72%
          - % pulmonary 71%
          - % bacteriologically confirmed among pulmonary 87%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.11 (0.06–0.17)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 213 14%
          - on antiretroviral therapy    
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  22
(12–32)
Estimated % of TB cases with MDR/RR-TB 0.98% (0.51–1.7) 6.9% (2.8–14)  
% notified tested for rifampicin resistance 45% 52% 971
MDR/RR-TB cases tested for resistance to second-line drugs   10
Laboratory-confirmed cases MDR/RR-TB: 19, XDR-TB: 3
Patients started on treatment **** MDR/RR-TB: 19, XDR-TB: 3
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 72% 2 198
Previously treated cases, excluding relapse, registered in 2014 60% 52
HIV-positive TB cases, all types, registered in 2014 57% 210
MDR/RR-TB cases started on second-line treatment in 2013 57% 14
XDR-TB cases started on second-line treatment in 2013 50% 4
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (100–100)
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-09 Data: www.who.int/tb/data